BioNTech SE

Welcome to BioNTech's first quarter 2026 earnings call. I will now hand the call over to Doug Maffay, Vice President, Strategy and Investor Relations.

Please go ahead. Thank you, Operator. Good morning and good afternoon.

Thank you for joining BioNTech's first quarter 2026 earnings call. As a reminder, the slides we will use during this call and the corresponding press release can be found in the investor section of our website. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission, or SEC. Forward-looking statements on this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements. On slide three, you can find the agenda for today's call. I'm joined by the following members of BioNTech's management team. Ugo Shaheen, Chief Executive Officer and Co-Founder, Oslem Tureci, Chief Medical Officer and Co-Founder, and Ramon Zapata, Chief Financial Officer. Also available for the Q&A portion of today's call is Anne-Marie Hannekamp, our Chief Commercial Officer. With this, I'll hand the call over to Ugar.